Submitted:
08 March 2024
Posted:
12 March 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Procedure
2.2. Participants
2.3. Instruments
2.3.1. VSI
2.3.2. MAIA
- Noticing: Awareness of uncomfortable, comfortable, and neutral bodily sensations.
- Not-Distracting: Tendency to ignore or distract oneself from sensations of pain or discomfort.
- Not-Worrying: Emotional distress or worry associated with sensations of pain or discomfort.
- Attention Regulation: The ability to sustain and control attention to bodily sensations.
- Emotional Awareness: Awareness of the connection between bodily sensations and emotional states.
- Self-Regulation: The ability to regulate psychological discomfort through attention to bodily sensations.
- Body Listening: Active listening to the body for understanding.
- Trusting: Experiencing one’s own body as safe and reliable (subscales range: 0-5).
3. Results
3.1. Validity and Reliability of VSI-IT
3.2. Sensitivity and Discriminant Validity of the VSI-IT
3.2.1. The Ability of the VSI-IT to Discriminate between Various Pathological Conditions
3.2.2. The Ability of the VSI-IT to Discriminate Based on the Severity of Symptoms
3.3. Concurrent Validity of VSI-IT
| Variable | Visceral Sensitivity Index |
| Noticing | 0.277 ** |
| Not-distracting | -0.044 |
| Not-worrying | -0.414 ** |
| Attention regulation | -0.142 ** |
| Emotional awareness | 0.235 ** |
| Self-regulation | -0.135 * |
| Body Listening | 0.056 |
| Trusting | -0.302 ** |
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Appendix A
| Pienamente d’accordo | D’accordo | Parzialmente d’accordo | Parzialmente in disaccordo | In disaccordo | Fortemente in disaccordo | |
| 1. Temo che ogni volta che mangio durante il giorno, il gonfiore e la distensione della pancia peggioreranno. | □ | □ | □ | □ | □ | □ |
| 2. Divento ansioso quando vado in un nuovo ristorante. | □ | □ | □ | □ | □ | □ |
| 3. Mi preoccupo spesso per problemi alla pancia. | □ | □ | □ | □ | □ | □ |
| 4. Ho difficoltà a divertirmi perché non riesco a distogliere la mente dal disagio della pancia. | □ | □ | □ | □ | □ | □ |
| 5. Spesso temo di non riuscire ad avere un normale movimento intestinale. | □ | □ | □ | □ | □ | □ |
| 6. A causa della paura di sviluppare disturbi addominali, raramente provo cibi nuovi. | □ | □ | □ | □ | □ | □ |
| 7. Qualunque cosa mangi, probabilmente mi sentirò a disagio. | □ | □ | □ | □ | □ | □ |
| 8. Non appena sento fastidio addominale comincio a preoccuparmi e a sentirmi ansioso. | □ | □ | □ | □ | □ | □ |
| 9. Quando entro in un posto dove non sono mai stato, una delle prime cose che faccio è cercare un bagno. | □ | □ | □ | □ | □ | □ |
| 10. Sono costantemente consapevole delle sensazioni che ho nella mia pancia. | □ | □ | □ | □ | □ | □ |
| 11. Sento spesso che il fastidio alla pancia potrebbe essere segno di una grave malattia. | □ | □ | □ | □ | □ | □ |
| 12. Non appena mi sveglio, temo che avrò fastidio alla pancia durante il giorno. | □ | □ | □ | □ | □ | □ |
| 13. Quando sento disagio nel mio ventre, mi spavento. | □ | □ | □ | □ | □ | □ |
| 14. In situazioni stressanti, la mia pancia mi dà molto fastidio. | □ | □ | □ | □ | □ | □ |
| 15. Penso costantemente a ciò che sta accadendo nella mia pancia. | □ | □ | □ | □ | □ | □ |
References
- Labus, J. S., Bolus, R., Chang, L., Wiklund, I., Naesdal, J., Mayer, E. A., & Naliboff, B. D. (2004). The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Alimentary pharmacology & therapeutics, 20(1), 89–97. [CrossRef]
- Trieschmann, K., Chang, L., Park, S., Naliboff, B., Joshi, S., Labus, J. S., Sauk, J. S., Limketkai, B. N., & Mayer, E. A. (2022). The visceral sensitivity index: A novel tool for measuring GI-symptom-specific anxiety in inflammatory bowel disease. Neurogastroenterology and motility, 34(9), e14384. [CrossRef]
- Caballero-Mateos, A.M. Gut Feelings: The Psychological Impact of Inflammatory Bowel Disease. J. Clin. Med. 2023, 12, 3867. [Google Scholar] [CrossRef] [PubMed]
- Lind R, Lied GA, Lillestøl K, Valeur J, Berstad A: Do psychological factors predict symptom severity in patients with subjective food hypersensitivity? Scand J Gastroenterol 2010, 45:835–843.
- Saigo, T., Tayama, J., Hamaguchi, T., Nakaya, N., Tomiie, T., Bernick, P. J., Kanazawa, M., Labus, J. S., Naliboff, B. D., Shirabe, S., & Fukudo, S. (2014). Gastrointestinal specific anxiety in irritable bowel syndrome: validation of the Japanese version of the visceral sensitivity index for university students. BioPsychoSocial medicine, 8(1), 10. [CrossRef]
- Neverovskyi, A., Shypulin, V., & Mikhnova, N. (2023). Translation and validation of the Ukrainian version of the visceral sensitivity index for patients with irritable bowel syndrome. Przeglad gastroenterologiczny, 18(3), 313–319. 3. [CrossRef]
- Brown, T. A., Reilly, E. E., Murray, H. B., Perry, T. R., Kaye, W. H., & Wierenga, C. E. (2021). Validating the visceral sensitivity index in an eating disorder sample. The International journal of eating disorders, 54(6), 986–994. [CrossRef]
- Hayes, B., Burgell, R., Apputhurai, P., Garg, M., & Knowles, S. R. (2022). Extending the Common Sense Model to Explore the Impact of Visceral Sensitivity on Quality of Life in Inflammatory Bowel Disease. The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology, 33(2), 103–110. [CrossRef]
- Larussa T, Abenavoli L, Corea A, Procopio AC, Giubilei L, Vallelunga R, Polimeni N, Suraci E, Marasco R, Imeneo M, Boccuto L, Luzza F. Trends and characteristics associated with dietary triggers and psychological distress in patients with irritable bowel syndrome: a cross-sectional study. Eur Rev Med Pharmacol Sci. 2021 May;25(10):3752-3761. [CrossRef]
- Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A. The Multidimensional Assessment of Interoceptive Awareness (MAIA). PLoS One. 2012;7(11):e48230. [CrossRef]
- Schiller, D., Alessandra, N. C., Alia-Klein, N., Becker, S., Cromwell, H.C., Dolcos, F., …& Soreq, H. (2023). The human affectome. Neuroscience & Biobehavioral Reviews, 158:105450. [CrossRef]
- Atanasova, K., Lotter, T., Reindl W., Lis S., Multidimensional Assessment of Interoceptive Abilities, Emotion Processing and the Role of Early Life Stress in Inflammatory Bowel Diseases. Front Psychiatry. 2021 Jun 24; 12:680878. [CrossRef]
- Gîlcă-Blanariu, G. E., Șchiopu, C. G., Ștefănescu, G., Mihai, C., Diaconescu, S., Afrăsânie, V. A., ... & Ștefănescu, C. (2023). The intertwining roads between psychological distress and gut microbiota in inflammatory bowel disease. Microorganisms, 11(9), 2268. 9.
- Bruno, A., Rizzo, A., Muscatello, M. R. A., Celebre, L., Silvestri, M.C., Zoccali, R.A., & Mento, C. (2020). Hyperarousal scale: Italian cultural validation, age and gender differences, in a nonclinical population. International Journal of Environmental Research and Public Health, 17(4), 1176.
- Fracas, E.; Constantino, A.; Vecchi, M.; Buoli, M. Depressive and Anxiety Disorders in Patients with Inflammatory Bowel Diseases: Are There Any Gender Differences? Int. J. Environ. Res. Public Health 2023, 20, 6255. [Google Scholar] [CrossRef] [PubMed]
- Labus, J. S., Mayer, E. A., Chang, L., Bolus, R., & Naliboff, B. D. (2007). The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosomatic medicine, 69(1), 89–98. [CrossRef]
- Macaluso, F. S., Ventimiglia, M., Fries, W., Viola, A., Sitibondo, A., Cappello, M., ... & Sicilian Network for Inflammatory Bowel Disease (SN-IBD). (2021). A propensity score weighted comparison of vedolizumab and adalimumab in Crohn’s disease. Journal of Gastroenterology and Hepatology, 36(1), 105-111.
- Belvedere, A., Scoglio, R., Viola, A., Costantino, G., Sitibondo, A., Muscianisi, M., ... & Fries, W. (2021). A real world investigation on prevalence, clinical features, and therapy of inflammatory bowel disease in the city of Messina, Italy. Acta Bio Medica: Atenei Parmensis, 92(2).
- Viola, A., Fontana, A., Belvedere, A., Scoglio, R., Costantino, G., Sitibondo, A., ... & Fries, W. (2020). Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach. Scandinavian Journal of Gastroenterology, 55(10), 1176-1184.
- Yildrim, M., Turan, M. E., Albeladi, N.S., Crescenzo, P., Rizzo, A., Nucera, G., …& Chirico F. (2023). Resilience and perceived social support as predictors of emotional well-being. J Health Soc Sci, 8(1), 59-75.



| VSI-IT Item | Item factor loading |
|---|---|
| Item 1 | 0.67 |
| Item 2 | 0.74 |
| Item 3 | 0.83 |
| Item 4 | 0.83 |
| Item 5 | 0.82 |
| Item 6 | 0.78 |
| Item 7 | 0.80 |
| Item 8 | 0.83 |
| Item 9 | 0.71 |
| Item 10 | 0.58 |
| Item 11 | 0.76 |
| Item 12 | 0.83 |
| Item 13 | 0.76 |
| Item 14 | 0.72 |
| Item 15 | 0.84 |
| Healthy controls (N=164) | Crohn’s Disease (N=111) | Ulcerative Rectocolitis (N=180) | IBS (N=34) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| VSI-IT | M | SD | M | SD | M | SD | M | SD | |
| Item 1 | 2.31 | 1.668 | 3.26 | 1.367 | 3.19 | 1.468 | 2.94 | 1.455 | |
| Item 2 | 1.20 | 1.431 | 2.66 | 1.735 | 2.53 | 1.676 | 2.32 | 1.701 | |
| Item 3 | 1.96 | 1.543 | 3.77 | 1.270 | 3.75 | 1.303 | 3.12 | 1.647 | |
| Item 4 | 1.20 | 1.504 | 2.65 | 1.570 | 2.76 | 1.558 | 2.24 | 1.707 | |
| Item 5 | 1.45 | 1.560 | 3.37 | 1.414 | 3.44 | 1.503 | 3.44 | 1.397 | |
| Item 6 | 0.82 | 1.207 | 2.78 | 1.665 | 2.82 | 1.665 | 2.41 | 1.893 | |
| Item 7 | 0.89 | 1.324 | 2.22 | 1.603 | 2.29 | 1.629 | 2.03 | 1.547 | |
| Item 8 | 1.66 | 1.480 | 3.36 | 1.380 | 3.48 | 1.432 | 3.03 | 1.487 | |
| Item 9 | 0.94 | 1.313 | 3.00 | 1.868 | 3.22 | 1.802 | 1.53 | 1.482 | |
| Item 10 | 2.40 | 1.530 | 3.77 | 1.084 | 3.73 | 1.235 | 3.03 | 1.446 | |
| Item 11 | 1.10 | 1.373 | 2.71 | 1.410 | 2.95 | 1.503 | 1.88 | 1.533 | |
| Item 12 | 0.85 | 1.275 | 2.24 | 1.674 | 2.72 | 1.741 | 1.97 | 1.642 | |
| Item 13 | 1.65 | 1.497 | 3.09 | 1.462 | 3.31 | 1.454 | 2.74 | 1.729 | |
| Item 14 | 2.26 | 1.647 | 4.00 | 1.228 | 3.96 | 1.274 | 3.85 | 1.258 | |
| Item 15 | 0.92 | 1.242 | 2.64 | 1.565 | 2.91 | 1.520 | 2.41 | 1.725 | |
| Sample 1-Sample 2 | Test Statistic | Std. Error | Std. Test Statistic | Sig. |
|---|---|---|---|---|
| Healthy controls-Irritable bowel syndrome | -126.96 | 27.18 | -4.67 | 0.00 |
| Healthy controls-waiting for diagnosis | -142.36 | 44.91 | -3.17 | 0.00 |
| Healthy controls-Crohn’s disease | -175.91 | 17.74 | -9.92 | 0.00 |
| Healthy controls-Ulcerative rectocolitis | -189.49 | 15.59 | -12.16 | 0.00 |
| Irritable bowel syndrome-waiting for diagnosis | -15.40 | 50.01 | -0.31 | 0.76 |
| Irritable bowel syndrome-Crohn’s disease | 48.95 | 28.26 | 1.73 | 0.08 |
| Irritable bowel syndrome-Ulcerative rectocolitis | 62.53 | 26.96 | 2.32 | 0.02 |
| Waiting for diagnosis-Crohn’s disease | 33.55 | 45.57 | 0.74 | 0.46 |
| Waiting for diagnosis-Ulcerative rectocolitis | 47.13 | 44.78 | 1.05 | 0.29 |
| Crohn’s disease-Ulcerative rectocolitis | -13.58 | 17.40 | -0.78 | 0.44 |
| Sample 1-Sample 2 | Test Statistic | Std. Error | Std. Test Statistic | Sig. | Adj. Sig. a |
|---|---|---|---|---|---|
| Absent-mild | -44.18 | 16.44 | -2.69 | 0.01 | 0.04 |
| Absent-moderate | -66.93 | 15.36 | -4.36 | 0.00 | 0.00 |
| Absent-severe | -119.58 | 19.94 | -6.00 | 0.00 | 0.00 |
| Mild-moderate | -22.75 | 12.76 | -1.78 | 0.08 | 0.45 |
| Mild-severe | -75.40 | 18.01 | -4.19 | 0.00 | 0.00 |
| Moderate-severe | -52.64 | 17.04 | -3.09 | 0.00 | 0.01 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).